Introduction
A large proportion of the brain volume is thought to consist of space filled with extracellular matrix (ECM) (Rutka et al, 1988 ), yet electron microscopy and immunostaining show relatively low content of fibrous matrix proteins such as collagens, fibronectin and vitronectin (Rutka et al, 1988; Rucklidge et al, 1989; Stallcupe?a/., 1989; Asher etal, 1991; Gladson and Cheresh, 1991) , or basement membrane proteins, such as laminin (Hagg et al., 1989) . The heparan sulfate proteoglycan perlecan is only present in amyloid deposits of the brain (Snow et al., 1994) . Some of these ECM components are present in the embryonic brain; the various forms of laminin, in particular, are thought to play a major role in nervous tissue development as guidance molecules for nerve cell processes (Rutka et al., 1988) . As development is completed these matrix components are down-regulated to levels where they can be detected only with some difficulty by immunostaining and only in certain parts of the brain. Although quantitative studies have not been conducted, it appears that the brain ECM may primarily consist of a family of proteoglycans, which I propose to name lecticans, and two ECM components to which they bind, tenascins and hyaluronic acid.
Lectican family of proteoglycans in brain
Proteoglycans are important components of cell surfaces and ECMs, including those of the brain; they can regulate cell adhesion, neurite outgrowth, ECM assembly and tumor cell invasion (Ruoslahti, 1989) , and they also serve as cofactors and regulators of growth factors (Ruoslahti and Yamaguchi, 1991) . Of the several families of proteoglycans, members of the lectican family of proteoglycans appear to be particularly abundant in brain tissue.
Four members of the lectican family have been cloned: versican (Zimmermann and Ruoslahti, 1989) , aggrecan (Doege et al., 1991) neurocan (Rauch et al., 1992) and brevican (Yamada et al., 1994) . Like all proteoglycans, lecticans consist of a core protein and a glycosaminoglycan moiety. The lectican core proteins are large, ranging from 80 to 400 kDa in molecular weight. Their sequences are highly homologous, but all four are clearly products of distinct genes. The core proteins display an N-terminal hyaluronic acid-binding domain that is homologous to the cartilage link protein and to the homing receptor CD44 and a C-terminal domain comprised of EGF-like repeats, a C-type lectin motif and complement regulatory protein repeats ( Figure 1 ). These are the same structural units, albeit in a different order, as the ones that make up the carbohydratebinding adhesion receptors, selectins (Lasky, 1992) . The middle portion of the core proteins contains attachment sites for glycosaminoglycan chains, which are of the chondroitin sulfate variety. The length and structure of this part varies greatly among the members of the family. In addition, alternative splicings create variants of the individual lecticans (Dours- Zimmermann and Zimmermann, 1994) .
Versican is abundant in the brain, but is also expressed in many other tissues (Krusius et al., 1987; Schbnherr et al., 1991; LeBaron et al., 1992; Bignami et al., 1993) . Neurocan was identified in brain tissue; its mRNA is not detectable in several other tissues (Rauch et al., 1991 (Rauch et al., , 1992 . Brevican appears to be specifically expressed in the brain (Yamada et al., 1994) . Aggrecan is a proteoglycan characteristic of cartilage (Hascall, 1988) , but immunological data (see Hennig et al., 1993) and the presence of aggrecan cDNA clones in a brain cDNA library (E. Ruoslahti and S. Suzuki, unpublished data) suggest that aggrecan may also be expressed in brain tissue. In addition to the proteoglycan form, brain tissue also contains versican and brevican core proteins that lack the glycosaminoglycan (Bignami et al., 1993; Yamada et al., 1994) . Proteins known as glial hyaluronic acid-binding protein (Perides et al., 1992) and hyaluronectin (Delpech et al., 1989) appear to represent free N-terminal domains of versican and perhaps of one of the other members of the family.
Several additional large chondroitin sulfate proteoglycans that may also be members of the lectican family have been identified in brain tissue. These include Cat 301 (Fryer et al, 1992) , Tl antigen (Iwata and Carlson, 1993) and astrochondrin (Streit et al., 1993) , and there may be others (Herndon and Lander, 1990; Rauch et al, 1991) . The core proteins of these proteoglycans have not been cloned yet, so their relationship to the more fully characterized proteoglycans remains unclear. However, their expression patterns and some other properties suggest that these proteoglycans may not be identical to any of the four cloned members of the lectican family. Thus, the lectican family of hyaluronic acid-binding proteoglycans is a large one, and it also appears that at least four of the members of this family are preferentially expressed in central nervous tissue.
Lectican binding functions
What might be the significance of the predominance of lecticans in the central nervous tissue? The hyaluronic acid-binding property of lecticans is likely to be important in this regard. The addition of aggrecan to a hyaluronic acid-producing cell culture results in the formation of an organized hyaluronic acid-proteoglycan coat around the cells (Knudson, 1993) . Thus, the lecticans seem to play a role in the organization of a hyaluronic acid-proteoglycan ECM. In vivo this matrix contains link protein (Meyer-Puttlitz et al., 1995) , a 45 kDa protein that reinforces the interaction between hyaluronic acid and a proteoglycan.
The matrices containing different lecticans may be quite different in some of their properties, because lecticans vary greatly in length and in glycosaminoglycan content. Aggrecan, at least in the cartilage, carries as many as 100 chondroitin sulfate chains (Hascall, 1988) , whereas brain tissue versican contains only a few short chondroitin sulfate chains (Perides et al., 1992) . Moreover, both versican and brevican exist in the brain also in a form that is devoid of glycosaminoglycan (Bignami et al., 1993; Yamada et al., 1994) . Thus, depending on the nature of the lectican, a hyaluronic acid-proteoglycan complex can have a very different chondroitin sulfate content.
The selectin-type C-terminus of lecticans provides these proteoglycans with an additional recognition domain. The C-type lectin of this domain can bind simple sugars; this has been shown for aggrecan (Halberg et al., 1988) and versican (Ujita et al., 1994; Aspberg et al., 1995) . The target sugars for the lectins may be cell surface carbohydrates, as is the case with the selectins (Varki, 1994) . However, more significant may be the recently discovered interaction of the versican lectin domain with tenascin-R (see below).
Versican-tenascin interaction
The versican lectin, isolated as a recombinantly made 15 kDa protein, binds insolubilized fucose and /V-acetylglucosamine. As is characteristic of C-type lectins, this binding is calciumdependent. The lectin also recognizes in a calcium-dependent manner the ECM protein tenascin-R, both in gel blots and in solution (Aspberg et al., 1995) . Tenascin-R and versican have partially overlapping distributions in the brain; tenascin-R is particularly abundant in the granular layer of the cerebellum (Fuss et al, 1993) , and versican is seen at this same location. The versican lectin does not bind tenascin-C, which is closely related to tenascin-R. Instead, tenascin-C may be bound by neurocan (Hoffman et al., 1988; Grumet et al, 1994) , raising the exciting possibility that the individual lecticans may each interact with a distinct tenascin; there are two additional known members in the tenascin family (reviewed in Chiquet-Ehrisman et al, 1994) . Versican and brevican are produced by glial cells (Bignami et al, 1993; Yamada et al, 1994 ; R. Lebaron and E. Ruoslahti, unpublished data) , while neurocan appears to be made by neurons . However, Cat 301 is associated with surfaces of neurons (Fryer et al, 1992 ) . Cell-type specificities and distinct lectin specificities of the individual lecticans could form the basis of a recognition system similar to that constituted by the selectin family.
Lectican-assembled matrices: possible functions
Lectican interactions such as that of versican with tenascin-R, may result in the formation of unique matrices consisting of a lectican, a tenascin, and hyaluronic acid. Brain tissue appears to be rich in such matrices and, unlike other tissues that contain lecticans, the brain has little other matrix.
The chondroitin sulfate in proteoglycans has been found to be neurotrophic and can promote neurite outgrowth of some brain neurons (Faissner et al, 1994; Junghanse?a/., 1995) , and inhibit it in others (Milev et al., 1994; Don and Levine, 1995) , thus potentially regulating neuronal patterning (Brittis et al, 1992) . The abundance of lecticans in the central nervous system should make their chodroitin sulfate an important contributor to such trophic and regulatory activities.
The ECM of cartilage resembles that of the brain; it is rich in aggrecan and in hyaluronic acid, but unlike the brain matrix, contains abundant fibrous collagen. The aggrecan-hyaluronic acid complex appears to serve as a cushion in cartilage (Hascall, 1988) . These complexes bind a large quantity of water that is extruded when the cartilage is compressed and that returns when the compression is released. The brain may need a similar buffer against pressure, because it is confined within the skull. In this case the water released by the proteoglycan complexes could perhaps be transferred into the circulation. There is one other striking parallel between cartilage and central nervous tissues: tumors rarely invade these tissues. The resistance of the cartilage to tumor invasion has been attributed to inhibition of angiogenesis (e.g., Moses et al, 1992) , but other explanations seem possible. It is well known that tumors metastasize into the brain from other tissues. However, brain tissue, especially the white matter, tends to be resistant to tumor invasion (Paganetti et al, 1988) . In contrast, glial cell tumors, which arise in the central nervous system, readily invade brain tissue, as do early glial precursors (Paganetti et al, 1988; Espinosa de los Monteros et al, 1993) . Interestingly, gliomas rarely metastasize outside the brain (Russel and Rubinstein, 1977) , suggesting a specialization into the invasion of brain tissue. It may be the uniqueness of extracellular matrix that makes the central nervous system resistant to tumor cell invasion. Moreover, only glial cells may possess the mechanisms necessary to circumvent this resistance.
Chondroitin sulfate proteoglycans have been proposed as regulators of the growth of neuronal processes, and they may affect similarly other migration events in nervous tissues (e.g., Oakley and Tosney, 1991; Brittis et al, 1992) . Proteoglycans can inhibit the cell attachment activity of other matrix proteins (Ruoslahti, 1989) . Cells need traction from attachment to a substrate to migrate. One possibility is that the matrices dominated by lecticans provide insufficient traction for migrating cells. Alternatively, since lecticans are capable of binding to other molecules through their lectin domain, these lecticanbound molecules, such as tenascins, could generate signals that are inhibitory for nonneuronal cell migration. Thus, the distinct properties of the lectican-tenascin-hyaluronic acid matrices (Figure 2 ) may underlie some of the physical and biological properties characteristic of brain tissue; this unique ECM deserves further study.
